Abstract

Our findings suggest that, while incident uveitis is rare in patients with cancer treated with anti-PD-1/PD-L1 inhibitors, there is an increased risk in those with skin melanoma, warranting vigilant monitoring for uveitis in this subgroup.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call